Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways

Despite significant progress, advanced hepatocellular carcinoma (HCC) remains an incurable disease, and the overall efficacy of targeted therapy by Sorafenib remains moderate. We hypothesized that DCP (des-gamma-carboxy prothrombin), a prothrombin precursor produced in HCC, might be one of the reaso...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Shu-Xiang, Shi, Wen-Na, Song, Zhi-Yu, Wang, Shu-Qing, Yu, Xin-Feng, Gao, Zu-Hua, Qu, Xian-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095038/
https://www.ncbi.nlm.nih.gov/pubmed/27167344
http://dx.doi.org/10.18632/oncotarget.9168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095038/
https://www.ncbi.nlm.nih.gov/pubmed/27167344
http://dx.doi.org/10.18632/oncotarget.9168

Ejemplares similares